Search Results - "Prescilla, Randy"

Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial by Cork, Michael J, Lockshin, Benjamin, Pinter, Andreas, Chen, Zhen, Shumel, Brad, Prescilla, Randy

“…In young children, atopic dermatitis (AD) imposes a multidimensional burden on many aspects of their quality of life (QoL) and that of their families. LIBERTY…”
Get full text

Efficacy of Tranexamic Acid in Pediatric Craniosynostosis Surgery: A Double-blind, Placebo-controlled Trial by GOOBIE, Susan M, MEIER, Petra M, ZURAKOWSKI, David, SETHNA, Navil F, PEREIRA, Luis M, MCGOWAN, Francis X, PRESCILLA, Randy P, SCHARP, Laurie A, ROGERS, Gary F, PROCTOR, Mark R, MEARA, John G, SORIANO, Sulpicio G

“…Extensive blood loss is common in pediatric craniosynostosis reconstruction surgery. Tranexamic acid (TXA) is increasingly used to reduce perioperative blood…”
Get full text

Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis by Cork, Michael J., Thaçi, Diamant, Eichenfield, Lawrence F., Arkwright, Peter D., Chen, Zhen, Thomas, Ryan B., Kosloski, Matthew P., Dubost-Brama, Ariane, Prescilla, Randy, Bansal, Ashish, Levit, Noah A.

“…Background For children aged 6–11 years with uncontrolled severe atopic dermatitis (AD), 16 weeks of treatment with dupilumab resulted in substantial clinical…”
Get full text

Dupilumab treatment reduces caregiver-reported skin pain in patients with moderate-to-severe atopic dermatitis aged 6 months to 5 years by Paller, Amy S, Silverberg, Jonathan I, Gonzalez, Mercedes E, Schneider, Lynda C, Sidbury, Robert, Chen, Zhen, Bansal, Ashish, Wang, Zhixiao, Prescilla, Randy

“…Moderate-to-severe atopic dermatitis (AD) often has a profound impact on the quality of life of young children and their caregivers. One of the most burdensome…”
Get full text

Similarities and Differences in the Perception of Atopic Dermatitis Burden Between Patients, Caregivers, and Independent Physicians (AD-GAP Survey) by Paller, Amy S., Weidinger, Stephan, Capozza, Korey, Pink, Andrew E., Tang, Mark, Guillaume, Xavier, Praestgaard, Amy, Leclerc, Marjorie, Chuang, Chien-Chia, Thomas, Ryan B., Prescilla, Randy

“…Introduction Atopic dermatitis (AD)—a chronic inflammatory skin disease characterized by intense itching—can have a detrimental impact on quality of life…”
Get full text

Dupilumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years by Siegfried, Elaine C., Simpson, Eric L., Cork, Michael J., Arkwright, Peter D., Wine Lee, Lara, Chen, Zhen, Prescilla, Randy, Bansal, Ashish, Levit, Noah A., Rodríguez Marco, Ainara

“…Introduction Atopic dermatitis (AD) is heterogeneous in distribution pattern and clinical features. This analysis assessed the effect of dupilumab on the…”
Get full text

Dexmedetomidine Offers an Option for Safe and Effective Sedation for Nuclear Medicine Imaging in Children by Mason, Keira P., Robinson, Fay, Fontaine, Paulette, Prescilla, Randy

Get full text

Influence of Goldenseal Root on the Pharmacokinetics of Indinavir by Sandhu, Ranjeev S., Prescilla, Randy P., Simonelli, Thomas M., Edwards, David J.

“…Goldenseal root was identified as the most potent inhibitor of CYP3A4 in a study that tested 21 popular herbal products for in vitro inhibitory activity. The…”
Get full text

Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study by Guttman-Yassky, Emma, Silverberg, Jonathan I., Nemoto, Osamu, Forman, Seth B., Wilke, August, Prescilla, Randy, de la Peña, Amparo, Nunes, Fabio P., Janes, Jonathan, Gamalo, Margaret, Donley, David, Paik, Jim, DeLozier, Amy M., Nickoloff, Brian J., Simpson, Eric L.

“…Baricitinib, an oral selective inhibitor of Janus kinase 1 and Janus kinase 2, modulates proinflammatory cytokine signaling. The efficacy and safety of…”
Get full text

41657 Clinically Important Benefits in Infants and Young Children With Moderate-to-Severe Atopic Dermatitis not Achieving IGA 0/1 after 16 weeks of Dupilumab Treatment by Paller, Amy S., Siegfried, Elaine, Lockshin, Benjamin, Praestgaard, Amy, Shumel, Brad, Prescilla, Randy

Get full text

42260 Dupilumab Improves Family Quality of Life in Children Aged 6 months to 5 Years With Moderate-to-Severe Atopic Dermatitis by Paller, Amy, Simpson, Eric, Siegfried, Elaine, Preastgaard, Amy, Wang, Zhixiao, Prescilla, Randy

Get full text

52650 Dupilumab Treatment Shows Rapid and Consistent Improvement in Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 17 Years: Results From an Open-Label Extension Study by Siegfried, Elaine C., Simpson, Eric L., Cork, Michael J., Saeki, Hidehisa, Chen, Zhen, Simcox, Elizabeth, Prescilla, Randy

Get full text

336 Efficacy of dupilumab in infants and preschoolers with atopic dermatitis up to 1 year by Paller, Amy S, Siegfried, Elaine C, Xiao, Jing, Prescilla, Randy, Bansal, Ashish

“…Abstract Continuous use of several traditional systemic atopic dermatitis (AD) treatments in pediatric patients is not recommended due to safety concerns and…”
Get full text

43731 Dupilumab Reduces Itch in Children with Moderate-to-Severe Atopic Dermatitis Aged 6 Months to 5 Years by Paller, Amy S., Siegfried, Elaine C., Yosipovitch, Gil, Kwatra, Shawn G., Praestgaard, Amy, Wang, Zhixiao, Prescilla, Randy

Get full text

42924 Treatment-Emergent Adverse Events in Patients Aged 6 Months to 5 Years With Moderate-to- Severe Atopic Dermatitis Treated With Dupilumab in an Open-Label Extension Clinical Trial by Paller, Amy, Siegfried, Elaine, Sidbury, Robert, Cork, Michael, Pinter, Andreas, Xiao, Jing, Stanton, Sarah, Khokhar, Faisal, Bansal, Ashish, Prescilla, Randy

Get full text

27431 Dupilumab treatment improves health-related quality of life in children aged ≥6 to <12 years with severe atopic dermatitis by Irvine, Alan, Deleuran, Mette, Praestgaard, Amy, Delevry, Dimittri, Prescilla, Randy, Rossi, Ana B.

Get full text

26875 52-week laboratory safety findings from an open-label extension (OLE) study of dupilumab in adolescent patients with atopic dermatitis (LIBERTY AD PED-OLE) by Cork, Michael J., Lockshin, Benjamin, Blauvelt, Andrew, Chen, Zhen, Khokhar, Faisal A., Bansal, Ashish, Prescilla, Randy

Get full text

Dupilumab Improves Signs And Symptoms Of Severe Atopic Dermatitis In Children Aged 6–11 Years With And Without Comorbid Allergic Rhinitis by Beck, Lisa, Wollenberg, Andreas, Paller, Amy, Siegfried, Elaine, Chen, Zhen, Abramova, Alvina, Prescilla, Randy

Get full text

Dupilumab Improves Signs And Symptoms Of Severe Atopic Dermatitis In Children Aged 6–11 Years With And Without Comorbid Asthma by Boguniewicz, Mark, Sher, Lawrence, Paller, Amy, Siegfried, Elaine, Chen, Zhen, Prescilla, Randy, Shumel, Brad

Get full text

41817 Dupilumab Treatment Improves Sleep Quality in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis and Their Caregivers by Paller, Amy S., Simpson, Eric L., Siegfried, Elaine C., Cork, Michael J., Wollenberg, Andreas, Arkwright, Peter D., Praestgaard, Amy, Prescilla, Randy, Wang, Zhixiao, Rodriguez Marco, Ainara

Get full text